Unique ID issued by UMIN | UMIN000042481 |
---|---|
Receipt number | R000048368 |
Scientific Title | Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function. |
Date of disclosure of the study information | 2020/11/18 |
Last modified on | 2023/03/20 15:10:40 |
Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Japan |
type2 diabetes
Medicine in general | Endocrinology and Metabolism |
Others
NO
To investigate whether type2 diabetic inpatients who received semaglutide achieved better glycemic controls via protecting beta-cell function compared with those who did not.
Efficacy
Confirmatory
Not applicable
HbA1c levels in one year after discharge.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
2
Treatment
Medicine |
Semaglutide group:
In hospitalization, participants receive semaglutide 0.25mg once a week.
After discharge, participants receive semaglutide 0.50mg once a week in 12 weeks.
After 12 weeks of discharge, appropriate treatment will be given by judgement of the attending physician.
Control group:
Paticipants does not inject semaglutide until 12 weeks later discharge.
After 12 weeks of discharge, appropriate treatment will be given by judgement of the attending physician.
20 | years-old | <= |
Not applicable |
Male and Female
1) type2 diabetic inpatients
2) Patients who are over 20 years or older
3) Patinets never using GLP-1 receptor agonists
4) Diabetes duration within 10 years
5) Patients with the written informed consent
1) Patients with severe liver dysfunction
2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73)
3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0
4) Patinet with diabetic ketoacidosis
5) Patient with infection
6) Patients taking steroid
7) Patients with malignant tumor currently undergoing treatment
8) Pregnant or lactating woman
9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
80
1st name | Taichi |
Middle name | |
Last name | Minami |
Saiseikai Yokohamashi Nanbu Hospital
Department of Diabetes and Endocrinology
234-0054
3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan
045-832-1111
ksqdd034@yahoo.co.jp
1st name | Taichi |
Middle name | |
Last name | Minami |
Saiseikai Yokohamashi Nanbu Hospital
Department of Diabetes and Endocrinology
234-0054
3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan
045-832-1111
ksqdd034@yahoo.co.jp
Saiseikai Yokohamashi Nanbu Hospital
Saiseikai Yokohamashi Nanbu Hospital
Self funding
none
none
Saiseikai Yokohamashi Nanbu Hospital
3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan
045-832-1111
soumu01@nanbu.saiseikai.or.jp
NO
2020 | Year | 11 | Month | 18 | Day |
Unpublished
Open public recruiting
2020 | Year | 09 | Month | 28 | Day |
2020 | Year | 10 | Month | 06 | Day |
2020 | Year | 11 | Month | 04 | Day |
2022 | Year | 08 | Month | 31 | Day |
2020 | Year | 11 | Month | 17 | Day |
2023 | Year | 03 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048368